Ireland
--:--IST
Recruiting Not applicable

Pelvic Floor Muscle Training and Dynamic Neuromuscular Stabilization Exercises in Pediatric Patients

NCT07267364 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-11-11
Last updated
2026-10-06

Condition(s) studied

UrologyPediatric Disorder

Investigational drug(s) / intervention(s)

PFMT

PFMT: During PFMT, children are taught about the pelvic floor using video visuals and their awareness of the pelvic floor muscles is increased. They are then instructed on how to contract and relax their muscles to control urination. DNS exercises, on the other hand, is an exercise model that begins with spinal stabilization and focuses on muscle synergies. Participants in the study will be assessed twice: at the beginning and end of treatment, using the Voiding Disorders Symptom Score (VDSS), Pediatric Quality of Life Inventory 4.0 (PedsQL 4.0), the Bladder and Bowel Dysfunction Scale (BBS), Pediatric Incontinence Questionnaire (PIN-Q), Bristol gaita scale, Children's Depression Scale (CDS) and the Children's Body Image Scale.

Study summary

Dysfunctional voiding (DY) is one of the most common conditions in children. Various treatments are available. Participants will be randomly assigned to either PFMT (Group I) or PFMT+DNS (Group II). PFMT is the gold standard and routinely administered in hospitals for children diagnosed with dysfunctional voiding who are referred by a urologist. The PFMT group serves as the control group, and treatment will be scheduled for a total of 10 weeks, three days a week. During PFMT, children receive instruction about the pelvic floor using video visuals and increase awareness of their pelvic floor muscles. They are then instructed on how to contract and relax their muscles to control urination. DNS training is an exercise model that begins with spinal stabilization and addresses muscle synergies. Patients included in the study will be evaluated twice, at the beginning and at the end of the treatment: Voiding Disorders Symptom Score (VODS), Pediatric Quality of Life Inventory 4.0 (PedsQL 4.0), Pediatric Incontinence Questionnaire (PIN-Q), Bladder Bowel Dysfunction Scale (BDS), Bristol gaita scale, and Children's Body Image Scale.

Eligibility

Sex
ALL
Min age
5 Years
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Having been diagnosed with voiding dysfunction according to ICCS diagnostic criteria in a urology outpatient clinic, * Being 5-18 years old, * The child and their parent/guardian agree to participate in the study voluntarily and provide signed consent. Exclusion Criteria: * Organic pathologies such as urethral obstruction, ectopic ureter, spinal dysraphism, and diabetes * Diagnosis of VUR or neurogenic bladder * Cognitive and mental impairment * Having spina bifida * Being under 5 years of age * Receiving treatment such as PTC training or electrical stimulation

Primary outcome measure(s)

  • Voiding Disorders Symptom Scoring (VDSS) — 10 week
    There are 13 questions about lower urinary tract symptoms and 1 question about quality of life. Regarding nocturnal enuresis, the frequency and severity of nocturnal enuresis are questioned. The total score ranges from 0 to 35 points, with higher scores indicating greater symptom severity.
  • Bladder and Bowel Dysfunction Scale (BBDS) — 10 week
    The BBDS assesses the severity of bladder and bowel dysfunction symptoms in children. It comprises 14 items, with the first 13 evaluating symptom severity and the last item assessing questionnaire completion difficulty. Each item uses a 5-point Likert scale; higher scores reflect greater symptom severity. Turkish validity and reliability have been confirmed.

Trial sites (2)

FacilityCityRegionStatus
Necmettin Erbakan University Konya Konya Recruiting
Hanife Dogan Konya Konya Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07267364 on ClinicalTrials.gov ↗ ← All trials in Turkey